The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis
Yue You,Zhizhen Liu,Yannan Chen,Ying Xu,Jiawei Qin,Shuai Guo,Jia Huang,Jing Tao
DOI: https://doi.org/10.1007/s00592-020-01648-9
2021-01-08
Acta Diabetologica
Abstract:<span class="a-plus-plus abstract-section id-a-sec1"><h3 class="a-plus-plus">Aims</h3><p class="a-plus-plus">Mild Cognitive impairment (MCI) is common in type 2 diabetes mellitus (T2DM) patients. The impaired cognitive function had harmful effect on patients' diabetic conditions. This study aimed to estimate the prevalence of MCI in T2DM (T2DM-MCI) patients by conducting a systematic review and meta-analysis of observational studies.</p></span><span class="a-plus-plus abstract-section id-a-sec2"><h3 class="a-plus-plus">Methods</h3><p class="a-plus-plus">We carried out a literature search until June 1, 2020, for all observational studies in the following databases: Medline (PubMed), Web of Science, and Embase. Two independent reviewers initially screened the eligible articles. Then, a meta-analysis (random effects model) was conducted to estimate the prevalence of MCI in people with T2DM with STATA 16.</p></span><span class="a-plus-plus abstract-section id-a-sec3"><h3 class="a-plus-plus">Results</h3><p class="a-plus-plus">A total of 1808 articles were first considered after reading title and abstract, 12 of which remained after reviewing the full text. The combined prevalence of MCI in T2DM patients was estimated to be 45.0% (95% CI=36.0, 54.0). There was no significant heterogeneity through meta-regression and sensitivity analysis. Overall, Europe (<em class="a-plus-plus">n</em>=2, <em class="a-plus-plus">r</em>=36.6%, 95% CI=26.3, 46.9, I<sup class="a-plus-plus">2</sup>=82.3%) had a lower prevalence than Asia (<em class="a-plus-plus">n</em>=10, <em class="a-plus-plus">r</em>=46.4%, 95% CI=36.2, 56.6, I<sup class="a-plus-plus">2</sup>=98%). The overall prevalence in female patients (<em class="a-plus-plus">n</em>=14, <em class="a-plus-plus">r</em>=46.9%, 95% CI=34, 59.8, I<sup class="a-plus-plus">2</sup>=98.3%) was higher than that in male patients (<em class="a-plus-plus">n</em>=14, <em class="a-plus-plus">r</em>=38.8%, 95% CI=27, 50.7, I<sup class="a-plus-plus">2</sup>=98%). Subgroup analysis based on age demonstrated a lower prevalence in patients older than 60 years (<em class="a-plus-plus">n</em>=9, <em class="a-plus-plus">r</em>=44.3%, 95% CI=33.1, 55.6, I<sup class="a-plus-plus">2</sup>=98.3%) than patients younger than 60 years (<em class="a-plus-plus">n</em>=3, <em class="a-plus-plus">r</em>=46.4%, 95% CI=33.3, 59.5, I<sup class="a-plus-plus">2</sup>=91.2%).</p></span><span class="a-plus-plus abstract-section id-a-sec4"><h3 class="a-plus-plus">Conclusion</h3><p class="a-plus-plus">Our results demonstrate that the pooled estimated prevalence of mild cognitive impairment in type 2 diabetes mellitus patients is high worldwide, especially in China Asia. Primary care clinicians should pay more attention to the cognitive function of T2DM patients, as mild cognitive impairment is one of the risk factors for Alzheimer's disease.</p></span>
endocrinology & metabolism